Chronix Biomedical has now made available a laboratory developed test for the detection of risk factors highly associated with cancer. Through the simple process of drawing blood, we can now offer a test that can, with a high degree of accuracy, detect macromolecular mutations of DNA fragments in blood plasma, which are closely associated with cancer.
The Chronix Biomedical Cancer Evaluation blood test is a vast improvement to more traditional methods of determining the presence of cancer. The essential difference is that now for the first time, using proprietary Next Generation Genomic Sequencing we can detect cancer mutations of DNA in blood plasma. Advantages of this new technology, also referred to as Liquid Biopsy, is that we can now look at the entirety of the body and its health state relating to cancer. Current scanning and tissue biopsy can only look at a specific part of the body, such as the lung or prostate, and is usually only carried out on presentation of symptoms.
With Chronix Biomedical’s blood test we can now usefully evaluate asymptomatic clients when suspected being at high risk for developing cancer, for example individuals that smoke or have a genetic mutation in their family. This in most cases provides reassurance that all is well, however, in the event of a positive result, action can be taken and clients signposted to relevant specialists. Early detection of any cancer is vital to increasing the chance of a positive outcome.
For those with concerns specifically about breast, prostate or colorectal cancers, or those that are seeking clarity of their cancer risk generally, the Chronix blood test can provide you with an evaluation that allows the Doctor to make a more informed decision on further action.